JANX007 is Janux Therapeutics' investigational PSMA-directed TRACTr immunotherapy candidate for metastatic castration-resistant prostate cancer. It is in ongoing Phase 1 development with reported interim efficacy and manageable cytokine release syndrome profile, including exploration of every-two-week dosing and earlier-line settings. The drug remains investigational.
Janux Therapeutics has dosed the first participant in a Phase 1 clinical trial of JANX011, a CD19-targeted bispecific candidate designed using its ARM platform for autoimmune disease treatment.
DelveInsight releases three separate pipeline reports covering metastatic prostate cancer (80+ companies, 85+ drugs), iPSC-derived NK cells (12+ companies, 15+ drugs), and interstitial lung diseases (120+ companies, 120+ drugs), highlighting recent regulatory approvals, trial launches, and emerging therapies.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05519449 |
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) |
RECRUITING | PHASE1 |
